| Name | Title | Contact Details |
|---|
We want to share our innovations with you and learn from your feedback. Help us improve quality and design to make sure your system delivers from day one.
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
Our Zerigo Health Solution is the newest advance in the treatment of psoriasis, vitiligo & eczema - available at-home for your convenience!
DM Clinical Research is a clinical research company that connects pharmaceutical and research organizations to individuals seeking to power the advancement of medicine. They specialize in multiple therapeutic areas in Phase I-IV clinical trials.